The modern features of optimal therapy of cervical neoplasia on the background of bacterial vaginosis




high-grade intracervical neoplasia, high-risk human papilloma virus, bacterial vaginosis, loop excision, vaginal microbiome, epithelialization, decametoxinum


Research objective: to evaluate the effectiveness of vaginal decametoxinum in preparation for cervix excision (conization) in women with HSIL (cervical intraepithelial neoplasia (CIN) II) against the background of infection with high-risk human papilloma virus (HPV) in bacterial vaginosis (BV) and effectiveness of vaginal gel with decametoxinum and hyaluronic acid to improve repair in the postoperative period.
Materials and methods. 60 women with HSIL (CIN II) were examined against the background of high-risk oncogenic HPV infection and BV, who underwent loop cervix excision (conization). The main group (n = 30) on the eve of surgery was prescribed BV therapy with decametoxinum solution and oral metronidazole for up to 7 days, after cervical excision used vaginal gel with decametoxinum and hyaluronic acid for 14 days. The control group (30 patients) used oral metronidazole for 7 days for the BV treatment.
Visual cervix inspection was performed by colposcopy. Vaginal biocenosis was assessed by PCR. Elimination of oncogenic HPV strains was assessed by PCR.
Results. Decametoxinum in the combination therapy of HSIL (CIN II) caused faster and complete epithelialization of the wound surface than standard therapy (relative risk (RR) 0.27, 95% CI 0.10 – 0.71, p = 0.008). 3 months after decametoxinum use was determined by a significant increase in cases of vaginal microbiota normalization (RR 0.30, 95% CI 0.09 – 0.98, p = 0.047), an increase in the lactobacilli number in vaginal secretions (RR 0.31, 95% CI 0.11 – 0.84, p = 0.02). There was a statistically significant effect of decametoxinum on the oncogenic HPV elimination (RR 0.22, 95% CI 0.05 – 0.94, p = 0.04) after 6 months of combination therapy. No side effects of decametoxinum were noted either during therapy or at a later date.
Conclusions. Vaginal use of decametoxinum before and after loop cervix excision in women with HSIL (CIN II) on the background of high-risk HPV and BV showed acceleration of cervical reparative processes, pronounced antimicrobial effect, elimination of oncogenic HPV and safety.

Author Biographies

O.A. Taran, Vinnytsya National Pirogov Memorial Medical University, Vinnytsia

MD, associate professor of the Department of Obstetrics and Gynecology No. 1

V.O. Rud, National Pirogov Memorial Medical University, Vinnytsia

MD, professor, Department of Obstetrics and Gynecology No. 2

O.V. Bulavenko, Vinnytsia National Pirogov Memorial Medical University, Vinnytsia

MD, professor, head of Obstetrics and Gynecology Department No. 2

D.G. Konkov, National Pirogov Memorial Medical University, Vinnytsia

MD, professor, Obstetrics and Gynecology Department No. 1


  1. Volodko, N.A., Vinnytska, A.B., Kaminskyi, V.V., et al. “Ukrainian national consensus on the examination and treatment of women after primary cervical screening.” Reproductive Endocrinology 5.43 (2018): 8–14.
  2. Konkov, D.G., Starover, A.V., Bulavenko, O.V., Vozniuk, A.V. “The clinical efficiency of vaginal suppositories containing miramistin, for pregnant women with nonspecific vaginitis before installation of cervical pessaries.” Woman’s Health 7 (2017): 2–7.
  3. Konkov, D.G. “The features of clinical applying of probiotics in obstetric practice.” Woman’s health 3 (2020): 42–7.
  4. Konkov, D.G., Adamchuk, N.V., Klivak, V.V. “The features of complex therapy of bacterial vaginosis in pregnant women with cervical incompetence.” Reproductive endocrinology 4.54 (2020): 59–65.
  5. Taran, O.А., Bulavenko, O.V., Konkov, D.G., Lobastova, T.V. “Clinical advice in the optimization of the reparative processes of the uterine cervix due to destructive surgical involvement.” Woman’s health 3.139 (2019): 38–42.
  6. Taran, O.А., Bulavenko, O.V., Konkov, D.G., Lobastova, T.V. “The modern view on optimal therapy of HPV-associated pathology of cervix at the vaginal dysbiosis background's.” Reproductive endocrinology 6.44 (2018): 16–20.
  7. Aitken, C.A., Siebers, A.G., Matthijsse, S.M., et al. “Management and treatment of cervical intraepithelial neoplasia in the Netherlands after referral for colposcopy.” Acta Obstet Gynecol Scand 98.6 (2019): 737–46.
  8. Chao, Y.S., McCormack, S. HPV Self-sampling for primary cervical cancer screening: a review of diagnostic test accuracy and clinical evidence – An Update. Ottawa (ON). Canadian Agency for Drugs and Technologies in Health (2019).
  9. Champer, M., Wong, A.M., Champer, J., et al. “The role of the vaginal microbiome in gynaecological cancer.” BJOG 125.3 (2018): 309–15.
  10. Chehoud, C., Stieh, D.J., Bailey, A.G., et al. “Associations of the vaginal microbiota with HIV infection, bacterial vaginosis, and demographic factors.” AIDS 31.7 (2017): 895–904.
  11. Demarco, M., Egemen, D., Raine-Bennett, T.R., et al. “A study of partial human papillomavirus genotyping in support of the 2019 ASCCP Risk-Based Management Consensus Guidelines.” Journal of Lower Genital Tract Disease 24.2 (2020): 144–7.
  12. Jansen, E.E.L., Zielonke, N., Gini, A., et al. “Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review.” European Journal of Cancer 27 (2020): 207–23.
  13. Gilham, C., Sargent, A., Kitchener, H., Peto, J. “HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.” Health Technol Assess 23 (2019).
  14. Liang, Y., Chen, M., Qin, L., et al. “A meta-analysis of the relationship between vaginal microecology, human papillomavirus infection and cervical intraepithelial neoplasia.” Infect Agent Cancer 14 (2019): 29.
  15. Perkins, R.B., Guido, R.S., Castle, P.E., et al. “ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. 2019 ASCCP Risk-Based Management Consensus Guidelines Committee.” J Low Genit Tract Dis 24 (2020): 102–31.
  16. Sodhani, P., Gupta, S., Gupta, R., Mehrotra, R. Bacterial vaginosis and cervical intraepithelial neoplasia: is there an association or is co-existence incidental?. Asian Pac J Cancer Prev. 2017; 18(5): 1289-1292.
  17. Taran, O., Konkov, D., Lobastova, T. “The criteria for prognostic monitoring of cervical neoplasia.” The proceedings of the 27th biannual European Congress of Obstetrics and Gynaecology EBCOG. Bergen, Norway (2020).
  18. World Health Organization. Introducing and scaling up testing for human papillomavirus as part of a comprehensive programme for prevention and control of cervical cancer: a step-by-step guide. Geneva. WHO (2020).
  19. Tatarchuk, T.F., Kalugina, L.V., Petrova, G.A., et al. “Vaginal discharge syndrome. Problem with many unknowns.” Reproductive Endocrinology 53 (2020): 94–100.



How to Cite

Taran, O., Rud, V., Bulavenko, O., & Konkov, D. (2021). The modern features of optimal therapy of cervical neoplasia on the background of bacterial vaginosis. REPRODUCTIVE ENDOCRINOLOGY, (60), 101–106.